CN100400091C - Chinese remedy capsule for treating biliary tract disease - Google Patents
Chinese remedy capsule for treating biliary tract disease Download PDFInfo
- Publication number
- CN100400091C CN100400091C CNB2005101245030A CN200510124503A CN100400091C CN 100400091 C CN100400091 C CN 100400091C CN B2005101245030 A CNB2005101245030 A CN B2005101245030A CN 200510124503 A CN200510124503 A CN 200510124503A CN 100400091 C CN100400091 C CN 100400091C
- Authority
- CN
- China
- Prior art keywords
- solution
- water
- methanol
- chinese
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a Chinese traditional medicine, particularly to a Chinese traditional medicine capsule for treating biliary tract diseases, which is characterized in that the present invention is prepared by the following Chinese medicinal materials according to the weight ratio: 44.45% of virgate wormwood herb, 22.22% of curcuma root, 22.22% of desmodium styracifolium and 11.11% of bitter orange peel. The present invention is boiled for three times by adding water and respectively taking the Chinese medicinal materials in the raw materials of 1200g of virgate wormwood herb, 600g of curcuma root, 600g of desmodium styracifolium and 300g of bitter orange peel. The quantity of the added water of the first time is 6 times of the medicines, and the medicines are boiled for 3 hours. The quantities of the added water of the second time and the third time are respectively 4 times, and the medicines are boiled for 2 hours. Boiling solutions are merged. Medicine residues are filtered and removed, and filter liquor is decompressed and concentrated to relative density which is about 1.2(60DEG C). The medicine residues are dried at low temperature of 80DEG C, crushed, sieved, uniformly blended and loaded in capsules for 1000 granules; each capsule is loaded with 0.4g of medicine residues, namely that the present invention is obtained. The Chinese traditional medicine capsule for treating biliary tract diseases has good therapeutic effect, and is a preparation of 100% of pure Chinese traditional medicine. The present invention has no any auxiliary materials, and has the advantages of simple manufacture technology, safe admittance and no toxic or side effect.
Description
Technical field
The present invention relates to a kind of Chinese patent medicine, particularly a kind of Chinese medicine capsule for the treatment of biliary tract.
Background technology
Biliary tract is a kind of commonly encountered diseases of digestive tract disease, and clinical manifestation is a costa sternales pain, jaundice, and outbreak influences work and sleep because of violent abdominal pain causes the back radiated pain then often.The method of treatment gallbladder class disease has a lot, treatment with western, operative treatment is arranged usually or take Chinese patent medicine oral granular formulation, liquid preparation etc.Adopt western medicine, have the medicine leftover problem, will produce toxic and side effects like this; The employing expenses of surgical treatment is big, easily produces sequela problems such as postoperative recurrence, can bring misery to the patient; The Chinese patent medicine curative effect that has is not remarkable, and drug effect is not lasting, granule and liquid preparation, and consumption is big, and mouthfeel is bad, and the quality instability is inconvenient to take.Medicines such as some other YIDAN HEJI, cholagogic tablet, they add some adjuvants usually in medicine, in health giving quality, taking convenience degree, cost performance and safety certain deficiency is arranged.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine capsule for the treatment of biliary tract, its good effect is 100% pure Chinese medicinal preparation, does not have any adjuvant, and its processing technology is simple, and takes safety, and is without any side effects.
Technical scheme of the present invention is a kind of Chinese medicine capsule for the treatment of biliary tract, it is characterized in that: it is made by the Chinese medicinal herbs of following weight ratio, Herba Artemisiae Scopariae 44.45%, and Radix Curcumae 22.22%, Herba Lysimachiae 22.22%, Fructus Aurantii 11.11% is made.
The processing technology of the Chinese medicine capsule of described treatment biliary tract is: get Chinese medicinal herbs Herba Artemisiae Scopariae 1200 gram, Radix Curcumae 600 grams, Herba Lysimachiae 600 grams, Fructus Aurantii 300 grams and decoct with water 3 times, add 6 times of amounts for the first time, decocted 3 hours; Second and third time respectively adds 4 times of water gagings again, decocts 2 hours, and collecting decoction filters medicinal residues, when removing filtrate decompression and being concentrated into relative density and being 60 ℃ 1.2,80 ℃ of following cold drying, pulverizes, sieves, mixing, incapsulates, and adorns 0.4 gram, gets product for every.
Characteristics of the present invention are: 1, scientific formulation of the present invention is reasonable, therapeutical effect is obvious, and is evident in efficacy than other Cholagogue Mixture and western medicine biliary tract; 2, expect that by former finished product does not have any adjuvant and additives composition that has nothing to do with treatment; 3, it adopts water to carry---concentrating under reduced pressure---and the encapsulated technology of cold drying---micropowder---machine, technology is simple, and amount is guaranteed easily; 4, this preparation is the full extractum preparation of pure Chinese medicine.
Medical mechanism of the present invention: this product is optimized the ratio of visible component in the interior bile of body by bile metabolic process in the control agent, thereby impels bile acid, phospholipid in the bile to increase the minimizing of cholesterol, Phos; And the protection hepatocyte, improve liver function and promote the synthetic of ribonucleic acid in liver cell regeneration, hepatic glycogen and the nucleus, finally reach the effect of prevention and treatment biliary tract.
Below further set forth the beneficial effect of medicine of the present invention by the experiment of the test of pesticide effectiveness and clinical observation on the therapeutic effect.
Acute toxicity test of the present invention
1. test period :-1989 on the 5th JIUYUE of JIUYUE in 1989 12 days
2. be subjected to the reagent thing: the present invention.
3. the sample unit of providing: laboratory self-control, every gram dry powder are equivalent to crude drug 20 grams.
4. preparation: the time spent is mixed with suspension, shows brownish black, and PH is about 5.5.
5. animal feeding condition: ICR kind white mice is divided into cohort with sex supports, freely absorb solid feed and tap water, 22 ± 2 ℃ of room temperatures.Animal is provided by Shaanxi Province's Experimental Animal Center.
6. experimental technique and result
Get 20 of healthy ICR kind white mice, male and female half and half, body weight 18-22g, this product is made into 32% Cmax suspension, in 24 hours with 8g/kg body weight (160mg/20g) jar stomach three times, after this, observed seven days, mice all survives, and hair is glossy, ergasia, diet, defecation are all normal, and body weight obviously increases, mice is put to death in off-test, and perusal does not see that internal organs have color and form to change, as calculated, LD
50＞24g/kg is nontoxic level medicine, and the present invention is greater than 600 times of everyone dosage every day.
7. conclusion: Chinese crude drug LD in accordance with regulations
50＞32g/kg is nontoxic level medicine, and the present invention is greater than 480g/kg, so the present invention is nontoxic level medicine.
Long term toxicity test data of the present invention
1. date of test: 1989.9.21-1989.12.21
2. be subjected to the reagent thing: powdered drug of the present invention, brown-black powder, every gram dry powder is equivalent to crude drug 20g, and the time spent is mixed with suspension, and freezer storage is standby, and matched group is the boiling water that is chilled to room temperature.
The medicine unit of providing: the laboratory self-control, for its fluid extract oven dry pulverizing makes, every gram is equivalent to medicine 20 grams.
3. animal and feedstuff condition: healthy SD (Spmgue-Dawley) strain rat was seven ages in week, observed a week at laboratory rearing before the administration, and male and female divide cage conventional group feeding, freely ingested and drank water.Room temperature 15-25 ℃, and free key joint is arranged.
4. animal and the feedstuff unit of providing: Shaanxi Province's Experimental Animal Center.
5. test method and result
Get 80 of rat in age in week, body weight 68.0 ± 12.09g, male and female half and half, be divided into four groups at random, heavy dose of group is 2.4g/kg (be equivalent to crude drug amount 48g/kg and clinical everyone dosage every day 60 times), in agent body weight group be that 1.2g/kg body weight (be equivalent to crude drug 24g/kg and clinical everyone dosage every day 30 times) small dose group is 0.4g/kg body weight (is equivalent to crude drug amount 8g/kg and clinical everyone dosage every day 10 times), the 4th group is the blank group, gives the water with volume.Every day, the jar stomach was administered once, and continuous 90 days, weighed once in per ten days, observe its appetite, behavior, secretions, feces etc., if any animal dead, routine performs an autopsy on sb.At three the end of month, head-breaking is put to death, and gets blood specimen and carries out hematology and blood biochemistry checking, claims weight in wet base to main organs, asks dirty body ratio and carries out the pathological anatomy evaluation.
One, the observation of general situation
Offer medicine after 90 days, heavy dose of group, middle dosage group, the rat of small dose group is in hair luster, ergasia is ingested, and aspects such as feces relatively have no significant change with matched group, during the administration, body weight increases gradually, compares there was no significant difference (P＞0.05) (seeing Table 1) with matched group respectively.
Two, hematological examination
Experiment finishes, and the animal broken end is got blood, carries out hematological examination, red-cell count, and lencocyte count, platelet count, hemoglobinometry, the result will show that each index of large, medium and small dosage compares with matched group respectively.
Table one the present invention is to the influence of rat body weight (X ± SD)
Equal no significant difference (P＞0.05) (seeing Table 2).
Table 2 the present invention influence that indicate to rat blood (X ± SD)
Three, blood biochemical is learned and is checked
Experiment end broken end is got blood, acute serum SGPT routinely, plasma urea nitrogen and blood sugar detection.
The mensuration of A, clear SGPT:
Press King's method and measure serum SGPT content, with 520nm filter colorimetric, blank pipe zeroing the results are shown in Table 3 with 72-1 type spectrophotometer.
Table 3 the present invention is to the influence of rat serum SGPT (X ± SD)
| Group | Number of animals (N) | SGPT(u) | The P value |
| Matched group | 20 | 32.6±13.4 | |
| Small dose group | 20 | 37.3±13.9 | P＞0.05 |
| Middle dosage group | 20 | 35.1±21.4 | P＞0.05 |
| Big metering group | 20 | 36.2±21.5 | P＞0.05 |
Above result shows that the present invention gives oral 90 days of rat, and the animal serum glutamate pyruvate transaminase is not had obvious influence, and each dosage group measured value and matched group be no significant difference relatively.
The mensuration of B, blood plasma uremic nitrogen
Experiment end broken end is got blood and is measured urea nitrogen content in each treated animal blood plasma by diacetyl-oxime method, and with 520nml filter photoelectric colorimetry, blank pipe zeroing the results are shown in Table 4 with 72-1 type spectrophotometer.
Table 4 the present invention is to the influence of rat plasma blood urea nitrogen (X ± SD)
| Group | Number of animals (N) | Plasma urea nitrogen (mmol/L) | The P value |
| Matched group | 20 | 10.1±2.6 | |
| Small dose group | 20 | 9.0±3.7 | P＞0.05 |
| Middle dosage group | 20 | 7.4±2.4 | P＞0.05 |
| Big metering group | 20 | 7.4±2.8 | P＞0.05 |
The result shows: administration group of the present invention and matched group compare, and big metering group, middle dosage group plasma urea nitrogen content reduce highly significant.
C, the present invention are to the influence of fasting glucose content
Test last fasting and break end after 12 hours,, make blood plasma, measure blood sugar lowering by adjacent toluene saddle method with the potassium oxalate anticoagulant,, with 630nm filter colorimetric in 30 minutes, blank is managed zeroing with 72-1 type spectrophotometer, and record also calculates blood sugar content, result such as table 5.
Table 5 the present invention is to the influence of fasting glucose content (X ± SD)
| Group | Number of animals (N) | Blood sugar content | The P value |
| (mmol/L) | |||
| Matched group | 20 | 6.5±0.8 | |
| Small dose group | 20 | 6.1±1.7 | P＞0.05 |
| Middle dosage group | 20 | 5.2±1.2 | P＞0.05 |
| Big metering group | 20 | 5.5±1.1 | P＞0.05 |
The result shows that the present invention irritated stomach after 90 days, middle dosage group, the big metering group rat blood sugar content difference highly significant (P＞0.01) of comparing with matched group.
D, main dirty body ratio measuring
Experiment finishes rat is put to death, extract organs such as the heart, liver, spleen, lung, kidney, adrenal gland, thymus, uterus, testis rapidly, filter paper is removed bloodstain, is claimed its weight in wet base, asks the percentage ratio of internal organs weight and body weight, and each dosage and matched group compared, the results are shown in Table shown in 6,7.
Table 6 the present invention is to the influence () of the dirty body ratio of rat (unit: the % of X ± SD)
| Group | Heart body ratio | Liver body ratio | Spleen body ratio | Lung body ratio | Kidney body ratio |
| Matched group | 0.34±0.05 | 31±0.42 | 0.24±0.06 | 0.64±0.13 | 0.70±0.08 |
| Small dose group | 0.36±0.09 | 33±0.62 | 0.24±0.05 | 0.64±0.16 | 0.74±0.12 |
| Middle dosage group | 0.34±0.05 | 3.4±0.49 | 0.24±0.06 | 0.64±0.19 | 0.74±0.06 |
| Big metering group | 0.33±0.04 | 3.2±0.44 | 0.25±0.08 | 0.67±0.11 | 0.70±0.06 |
P＞0.05
Table 7 the present invention is to the influence (two) of the dirty body ratio of rat (unit: the % of X ± SD)
| Group | Adrenal gland's body is than * 10 -3 | Thymus body ratio | The body of uterus ratio | The testis body of epididymis is than (two) |
| Matched group | 19±45 | 0.13±0.04 | 0.32±0.09 | 183±0.31 |
| Small dose group | 19±58 | 0.11±0.04 | 0.27±0.08 | 190±0.28 |
| Middle dosage group | 19±60 | 0.10±0.03 | 0.29±0.04 | 195±0.36 |
| Heavy dose of group | 19±50 | 0.10±0.05 | 0.24±0.04 | 177±0.47 |
P＞0.05
Above result of the test shows: the dirty body of organ of each group is than relatively not having significant difference (P＞0.05) with matched group.
E, pathological examination
When off-test, put to death animal, extract organs such as the heart, liver, spleen, lung, kidney, adrenal gland, thymus, testis, uterus and ovary, perusal and immediately routine draw materials, fix with 10% formalin solution, paraffin embedding, shear, HE dye.Carry out histological observation.The result shows that the rat dispensing is after 90 days, and animal organ's histiocyte form of each administration group and matched group relatively do not have evident difference, does not find that all pathologic changes.
The chronic toxicity test of three kinds of dosage the present invention to two kinds of sex rat carried out in this test.The result shows: the weight of animals of (1) each administration group (large, medium and small dosage), and food-intake, outward appearance, behaviors etc. are generally in order.(2) each index of hematology and serum SGPT inspection is all normal, and big or middle dosage group can make the plasma urea nitrogen content of reflection renal function reduce, and the blood sugar content measured value is reduced.The former does not have damaging action to renal function at explanation, and the latter may be relevant with reinforcement carbohydrate metabolism.(3) each dirty body is than comparing no significant difference with matched group, and the tissue morphology inspection does not find that all pathologic changes.
Think thus: herbal mixture agent the present invention did not find tangible toxic reaction in oral 90 days to the rodent rat.
Effect experiment: the clinical observation of Drug therapy biliary tract of the present invention and contrast test
1, patient totally 300 people, age 30-70 year, wherein male 130 examples, women 170 examples.
2, clinical manifestation: facial jaundice, gallbladder rib pain, lack of appetite is indigestion and loss of appetite, abdominal distention, appetite descend, detest greasy, constipation, bitter taste, weak, body is stranded, vexed, the feeling of fullness sense of gastral cavilty portion is obvious, pale tongue yellow fur, stringy and tense pulse.
3, Therapeutic Method: 300 people are divided into 3 groups, and every group 100 people takes different pharmaceutical respectively.
Take oral 3 times of every day of the present invention for first group, one time 5,30 days is a course of treatment, serve on 2 courses of treatment.
Take oral 3 times of YIDAN HEJI every day for second group, a 20ml, 30 days is a course of treatment, serve on 2 courses of treatment.
Take the Western medicine Phenylpropanol for the 3rd group, oral 3 times of every day, one time 2 ball, 30 days is a course of treatment, serve on 2 courses of treatment.
4, efficacy assessment standard:
First group of produce effects: symptom, sign disappears, and observes 3 months no recidivists.
Second group of little effect: symptom, sign is obviously alleviated.
The 3rd group of improvement: symptom, sign no change.
5, therapeutic outcome: (seeing Table)
In a word, after logotype two courses of treatment, compare, take the present invention 100 people, cure rate 23.00%, obvious effective rate 37.00%, effective percentage 35.00%, inefficiency 5.00% with similar medicine.Total effective rate 95.00%.
The specific embodiment
Further set forth the preparation method of medicine of the present invention below with embodiment.
The present invention gets raw material Chinese medicinal herbs Herba Artemisiae Scopariae 1200g respectively, Radix Curcumae 600g, and Herba Lysimachiae 600g, Fructus Aurantii 300g decoct with water 3 times, and adding water for the first time is 6 times of amounts of medicine, decocts 3 hours.Second and third time respectively adds 4 times of water gagings, decocts 2 hours, and collecting decoction filters medicinal residues, remove, filtrate decompression is concentrated into relative density and is about 1.2 (60 ℃), in 80 ℃ of following cold drying, pulverizes, sieves, mixing, incapsulate, make 1000, adorn 0.4 gram for every, promptly.
Usage and dosage: oral, one time 5,3 times on the one.Specification: every dress 0.4g.Storage: sealing, put dry place.
Every of this product contains naringin (C
25H
12O
14) must not be less than 0.8mg.
Function of the present invention cures mainly: clearing away heat-damp and promoting diuresis, 'Shugan Lidan '.Be applicable to stagnation of QI due to depression of the liver, the costalgia that dampness-heat in the liver and gallbladder disease causes, the improvement of stomachache, symptom such as lack of appetite is indigestion and loss of appetite.
Drug inspection: character, this product are capsule, and content is granule or the powder of sepia to brownish black, mildly bitter flavor.
Differentiate:
(1) gets this product content 2g, add methanol 20ml, supersound process 30 minutes, filter, filtrate evaporate to dryness, residue add water 5ml makes its dissolving, water liquid is by polyamide column (glass column, internal diameter 1.2cm, 2g, the 50-80 order) water 30ml eluting discards water liquid, reuse 70% ethanol 50ml eluting, collect 70% ethanol elution, evaporated under reduced pressure, residue add methanol 2ml makes dissolving, as need testing solution.Other gets Herba Artemisiae Scopariae control medicinal material 10g, smashs to pieces, adds water 200ml, soaks 30 minutes, and reflux 1 hour filters while hot, and filtrate decompression evaporate to dryness, residue add that water 10ml is damp and hot to make its dissolving, shine medical material solution in pairs with legal system.Get the naringin reference substance again, add methanol and make the solution that every 1ml contains 1mg, in contrast product solution.According to thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000) test, draw each 2 μ l of above-mentioned three kinds of solution, put respectively on same polyamide film, with 36% acetic acid is developing solvent, launch, take out, dry, spray is with 1% aluminum chloride alcoholic solution, oven dry is put under the ultraviolet light (365 μ m) and is inspected, in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show same color 1-2 fluorescence speckle.With the corresponding position of reference substance chromatograph on, the fluorescence speckle of same color.
(2) get this product content 6g, add methanol 30ml, supersound process 20 minutes, filtration, filtrate, filtrate evaporate to dryness, residue add methanol 2ml makes dissolving, as need testing solution.Other gets Radix Curcumae control medicinal material powder 5g, adds methanol 30ml, and supersound process 20 minutes filters, and filtrate evaporate to dryness, residue add warm dissolving, the medical material solution in contrast of making of methanol 2ml.Get curcumenol reference substance 2mg again, add methanol and make the solution that every 1ml contains 1mg, in contrast product solution.Test according to thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000), draw each 5 μ l of above-mentioned three kinds of solution, putting in same usefulness 0.5% carboxymethylcellulose sodium solution respectively is on the silica gel g thin-layer plate of adhesive, with benzene-chloroform-ethanol (49: 49: 2) is developing solvent, launch, take out, dry, spray is with 10% phosphomolybdic acid ethanol solution solution, and it is clear to dry by the fire to the speckle colour developing at 106 ℃.In the test sample chromatograph, be on control medicinal material and the corresponding position of reference substance chromatograph, show the speckle of same color.
Check: should meet every regulation relevant under the capsule item (appendix I1 of Chinese Pharmacopoeia version in 2000)
Assay: measure according to high performance liquid chromatography (appendix VID of Chinese Pharmacopoeia version in 2000).
Chromatographic condition and system are tested with property: with octadecylsilane chemically bonded silica is filler, and acetonitrile-water (20: 80) is a mobile phase; Detect wavelength 283nm, number of theoretical plate calculates by the naringin peak should be not less than 2000.
The preparation of reference substance solution: it is an amount of to be taken at 110 ℃ of naringin reference substances that are dried to constant weight, and accurate the title decides, and adds methanol and makes the solution that every 1ml contains 60 μ g, promptly.
The preparation of need testing solution: get the content under this product device difference item, mixing, porphyrize, get about 1g, the accurate title, decide, and adds methanol 30ml, supersound process 30 minutes (power 260w) filters, and filtrate is put in the 50ml measuring bottle, and residue and container man methanol divide washing for several times on a small quantity, cleaning mixture is filtered in the same measuring bottle, add methanol to scale, shake up, filter with microporous filter membrane (0.45 μ m), get filtrate, promptly.
Algoscopy: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject chromatograph of liquid, measure, promptly.
Claims (3)
1. Chinese medicine capsule for the treatment of biliary tract, it is characterized in that: it is made by the Chinese medicinal herbs of following weight ratio, Herba Artemisiae Scopariae 44.45%, Radix Curcumae 22.22%, Herba Lysimachiae 22.22%, Fructus Aurantii 11.11% is made.
2. the processing technology of the Chinese medicine capsule of described treatment biliary tract is: get Chinese medicinal herbs Herba Artemisiae Scopariae 1200 gram, Radix Curcumae 600 grams, Herba Lysimachiae 600 grams, Fructus Aurantii 300 grams and decoct with water 3 times, add 6 times of amounts for the first time, decocted 3 hours; Second and third time respectively adds 4 times of water gagings again, decocts 2 hours, and collecting decoction filters medicinal residues, when removing filtrate decompression and being concentrated into relative density and being 60 ℃ 1.2,80 ℃ of following cold drying, pulverizes, sieves, mixing, incapsulates, and adorns 0.4 gram, gets product for every.
3. a kind of Chinese medicine capsule for the treatment of biliary tract according to claim 1 is characterized in that: the drug inspection of the Chinese medicine capsule of described treatment biliary tract;
(1) gets this product content 2g, add methanol 20ml, supersound process 30 minutes, filter, filtrate evaporate to dryness, residue add water 5ml makes its dissolving, water liquid is glass column internal diameter 1.2cm by polyamide column, 2g, 50-80 order, water 30ml eluting discards water liquid, reuse 70% ethanol 50ml eluting, collect 70% ethanol elution, evaporated under reduced pressure, residue add methanol 2ml makes dissolving, as need testing solution; Other gets Herba Artemisiae Scopariae control medicinal material 10g, smashs to pieces, adds water 200ml, soaks 30 minutes, and reflux 1 hour filters while hot, and filtrate decompression evaporate to dryness, residue add that water 10ml is damp and hot to make its dissolving, shine medical material solution in pairs with legal system; Get again and take out skin cream reference substance, add methanol and make the solution that every 1ml contains 1mg, product solution in contrast, press appendix VIB test of Chinese Pharmacopoeia version in 2000 according to thin layer chromatography, draw above-mentioned three kinds of each 2ul of solution, put respectively on same polyamide film, with 36% acetic acid is developing solvent, launch, take out, dry, spray is with 1% aluminum chloride alcoholic solution, oven dry is put under the ultraviolet light 365um and is inspected, in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show same color 1-2 fluorescence speckle, with the corresponding position of reference substance chromatograph on, the fluorescence speckle of same color;
(2) get this product content 6g, add methanol 30ml, supersound process 20 minutes, filtration, filtrate, filtrate evaporate to dryness, residue add methanol 2ml makes dissolving, as need testing solution; Other gets Radix Curcumae control medicinal material powder 5g, adds methanol 30ml, and supersound process 20 minutes filters, and filtrate evaporate to dryness, residue add warm dissolving, the medical material solution in contrast of making of methanol 2ml; Get raft art alcohol reference substance 2mg again, add methanol and make the solution that every 1ml contains 1mg, product solution in contrast, press appendix VIB test of Chinese Pharmacopoeia version in 2000 according to thin layer chromatography, draw above-mentioned three kinds of each 5ul of solution, putting in same usefulness 0.5% carboxymethylcellulose sodium solution respectively is on the silica gel g thin-layer plate of adhesive, was developing solvent with benzene-chloroform-ethanol by 49: 49: 2, launched, and took out, dry, spray is with 10% phosphomolybdic acid ethanol solution solution, and it is clear to dry by the fire to the speckle colour developing at 106 ℃, in the test sample chromatograph, be on control medicinal material and the corresponding position of reference substance chromatograph, show the speckle of same color;
Check: should meet every regulation relevant under the capsule item by appendix I1 of Chinese Pharmacopoeia version in 2000,
Assay: press appendix VID of Chinese Pharmacopoeia version in 2000 according to high performance liquid chromatography and measure;
Chromatographic condition and system are tested with property: with octadecylsilane chemically bonded silica is filler, and acetonitrile-water was a mobile phase by 20: 80; Detect wavelength 283nm, number of theoretical plate should be not less than 2000 by taking out the calculating of skin glycosides peak;
The preparation of reference substance solution: be taken at 110 ℃ be dried to constant weight to take out skin glycosides reference substance an amount of, accurately claim surely, add methanol and make the solution that every 1ml contains 60ug, promptly;
The preparation of need testing solution: get the content under this product device difference item, mixing, porphyrize, get about 1g, the accurate title, decide, and adds methanol 30ml, supersound process 30 minutes, power 260w filters, and filtrate is put in the 50ml measuring bottle, residue and container man methanol divide washing for several times on a small quantity, and cleaning mixture is filtered in the same measuring bottle, adds methanol to scale, shake up, filter with the 0.45um microporous filter membrane, get filtrate, promptly;
Algoscopy: accurate respectively reference substance solution and each 10ul of need testing solution of drawing, inject chromatograph of liquid, measure, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101245030A CN100400091C (en) | 2005-12-04 | 2005-12-04 | Chinese remedy capsule for treating biliary tract disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101245030A CN100400091C (en) | 2005-12-04 | 2005-12-04 | Chinese remedy capsule for treating biliary tract disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1814255A CN1814255A (en) | 2006-08-09 |
| CN100400091C true CN100400091C (en) | 2008-07-09 |
Family
ID=36906686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101245030A Active CN100400091C (en) | 2005-12-04 | 2005-12-04 | Chinese remedy capsule for treating biliary tract disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100400091C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105213962A (en) * | 2014-07-01 | 2016-01-06 | 胡进前 | Medicament capsule for the treatment of gallbladder disease and preparation method thereof |
| CN106110220B (en) * | 2016-08-22 | 2020-01-07 | 陕西盘龙药业集团股份有限公司 | Preparation process of Chinese patent medicine for treating biliary tract diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1304730A (en) * | 2000-07-25 | 2001-07-25 | 刘兰荣 | Chinese medicine for treating cholecystitis |
-
2005
- 2005-12-04 CN CNB2005101245030A patent/CN100400091C/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1304730A (en) * | 2000-07-25 | 2001-07-25 | 刘兰荣 | Chinese medicine for treating cholecystitis |
Non-Patent Citations (2)
| Title |
|---|
| 胆囊炎合剂治疗慢性胆囊炎. 徐义熙.浙江中医杂志，第21卷第7期. 1986 |
| 胆囊炎合剂治疗慢性胆囊炎. 徐义熙.浙江中医杂志，第21卷第7期. 1986 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1814255A (en) | 2006-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110455965B (en) | Preparation method of pharmaceutical composition and HPLC fingerprint spectrum establishment method thereof | |
| CN101856449B (en) | Chinese medicinal composition for clearing heat and promoting diuresis, activating blood and treating stranguria, preparation method and quality detection method | |
| CN101091765A (en) | Medicinal comsns-and usage for preventing and treating diabets mellitus | |
| CN105687994B (en) | A kind of Chinese medicine composition and preparation method thereof for treating chronic renal failure | |
| CN1299742C (en) | Medicine for treating diabetes, and its prepn. method | |
| CN1985864B (en) | Medicine composition prepared mainly from glycyrrhizic acid or its salt, ginseng and glossy ganoderma | |
| CN1709341B (en) | Medicinal composition for nourishing qi to invigorate spleen, and its preparing method and use | |
| CN101385785A (en) | Traditional Chinese medicine composition for treating hyperlipemia, preparation and quality control method thereof | |
| CN102068507A (en) | Preparation method of Chinese medicinal capsules for tonifying lung and activating blood circulation | |
| CN100400091C (en) | Chinese remedy capsule for treating biliary tract disease | |
| CN101313971B (en) | Chinese medicine composition for treating nephropathy | |
| CN102526427A (en) | Chinese medicinal composition for treating gastrointestinal diseases and quality inspection method | |
| CN102755369A (en) | Traditional Chinese medicine composition used for treating oral diseases, preparation process thereof, and quality detection method thereof | |
| CN101336986A (en) | Medicine composition and preparation method and quality control method thereof | |
| CN103316074B (en) | Medicine composite of halenia corni extract, astragalus extract and liquorice extract as well as preparation and application of medicine composite | |
| Hao et al. | Echinops Spp. Polysaccharide B Ameliorates Metabolic Abnormalities in a Rat Model of Type 2 Diabetes Mellitus. | |
| CN101632746B (en) | Medicament for treating ulcerative colitis and preparation method thereof | |
| CN1954838B (en) | Medical composite of antineoplastic | |
| CN101274037B (en) | Detection method of composition for curing skin pruritus | |
| CN1954839B (en) | Medical composition prepared by caulis Marsdeniae Tenacissimae, ginseng and astragalus root | |
| CN1209138C (en) | Medicine composition for tumour and its preparation method | |
| CN100355440C (en) | Compound Chinese medicinal preparation for treating type II diabetes and lowering blood sugar and its preparation method | |
| CN1970001B (en) | Pharmaceutical composition comprising kurarinone, magnolia vine fruit and ginseng for treating hepatitis | |
| CN1306949C (en) | Tendon relaxing and dampness removing traditional Chinese medicine compound preparation and preparation method thereof | |
| CN1977887B (en) | Medicinal composition for treating hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SHAANXI PANLONG PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: SHANXI RDRAGON PHARMACEUTICAL GROUP CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 711400 Panlong eco industrial park, Zhashui County, Shaanxi Province Patentee after: Shaanxi Panlong Pharmaceutical Group Co., Ltd. Address before: 710065, No. 6, Jixiang building, No. 298 Jixiang West Road, Shaanxi, Xi'an Patentee before: Shanxi Rdragon Pharmaceutical Group Co., Ltd. |